Three Brands of OTC Naloxone Now Exist. Competition Alone Won't Save Lives.
The FDA cleared Rextovy on June 16 — Amphastar's 4mg nasal spray joins Narcan and RiVive. What more brands mean for access, and what they don't fix.
On June 16, the FDA cleared Rextovy — Amphastar Pharmaceuticals’ 4mg naloxone hydrochloride nasal spray — for over-the-counter sale without a prescription, pharmacist consultation, or physician visit. It is the same active ingredient and same dose as Narcan, the original OTC naloxone that cleared in 2023. Rextovy is the third such product on shelves, after Narcan and RiVive.
The FDA’s announcement quoted the now-familiar statistic: overdose deaths have fallen from a peak of 111,451 in the 12-month period ending August 2023 to 68,632 in the period ending December 2025. Expanded naloxone access is part of that story. The agency’s position — and the position of every major public health organization — is that more brands mean more availability, more competition that may reduce prices, and more supply-chain resilience if any single manufacturer has production problems.
That’s all true. But “available over the counter” and “in the hands of the person who needs it” are not the same thing. The distribution problem hasn’t been solved by making naloxone prescription-free. In rural Arizona, in tribal communities, in the neighborhoods where overdose deaths are still rising, the nearest pharmacy that stocks any naloxone — Narcan, RiVive, or now Rextovy — is not always within reach. A third brand on a CVS shelf in Scottsdale doesn’t get naloxone to a 22-year-old using alone in a group home in Yuma.
The harm reduction organizations that have actually moved naloxone at scale — community health workers going door to door in public housing, needle exchange vans, emergency department distribution programs — are the distribution channel that matters most for the populations experiencing the most deaths. Those organizations run on grant funding. That funding is under active federal review.
The multiplication of OTC brands is unambiguously good. The pretense that it closes the distribution gap is the part that warrants scrutiny. The drug can be bought without a prescription by anyone who walks into a pharmacy. The people dying in Maricopa County’s highest-overdose zip codes are, in many cases, not walking into pharmacies.
Rextovy’s approval is a useful addition to an incomplete solution. The incomplete part is the part that needs attention.
Follow harm reduction policy and the opioids series for ongoing coverage of naloxone access and overdose prevention.
Sources Cited
- 01.A
- 02.B
Filed Under
harm-reductionpolicyNaloxoneFDAHarm Reduction
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Ketamine Was Invented to Be the Gentler Drug. Its Bill Comes Due in the Bladder.
Ketamine bladder damage, explained in plain language: how the drug works, why regular use can shrink and scar the bladder, what 'K-cramps' are, and what actually lowers the risk. Plus the history of a drug built to replace PCP.
Harm ReductionSmoke, Vape, Edible, Dab: When Cannabis Has a Form for Every Hour, It Has You
People who use cannabis in nearly every form had about 67% rates of cannabis use disorder versus 15% for mostly-edible users. What that means, what it doesn't, and the one question worth asking yourself.
Harm ReductionThe Alcohol Medicine That Pays for Itself Has Been Sitting on the Shelf Since 1994
Columbia researchers found naltrexone plus counseling for people with early alcohol-related liver scarring costs less and adds life. Here's what the medicine does, why almost nobody is offered it, and how to ask.